Update on Locoregional Therapies for Cholangiocellular Carcinoma

Cancers (Basel). 2023 Apr 19;15(8):2368. doi: 10.3390/cancers15082368.

Abstract

Locoregional therapy options for CCA are used, in particular, for non-resectable tumors and aim to reduce tumor viability or delay tumor growth and ultimately prolong overall survival. In addition to local ablative procedures such as radiofrequency- or microwave-ablation, transarterial procedures such as transarterial embolization (TAE), transarterial chemoembolization (TACE), or selective internal radiotherapy (SIRT) play a major role. In particular, in combination with advances in molecular medicine and immunotherapy, there has been a further development in the therapy of primary malignant liver tumors in recent years. In this review, we analyze data from recent studies and examine the implications for therapy of CCA, particularly with regard to the combination of locoregional therapies with modern systemic therapies.

Keywords: cholangiocellular carcinoma; interventional radiology; locoregional therapy; systemic therapy.

Publication types

  • Review

Grants and funding

This research received no external funding.